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Summary Clinical	myelin	diseases,	and	our	best	experimental	approximations,	are	complex	entities	in	which	demyelination	and	remyelination	proceed	unpredictably	and	concurrently.	These	features	can	make	it	difficult	to	identify	mechanistic	details.	Toxin-based	models	offer	lesions	with	predictable	spatiotemporal	patterns	and	relatively	discrete	phases	of	damage	and	repair:	a	simpler	system	to	study	the	relevant	biology	and	how	this	can	be	manipulated.	Here,	we	discuss	the	most	widely	used	toxin-based	models,	with	a	focus	on	lysolecithin,	ethidium	bromide	and	cuprizone.	This	includes	an	overview	of	their	respective	mechanisms,	strengths	and	limitations	and	step-by-step	protocols	for	their	use.	
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1. Introduction The	causes	of	demyelinating	disease	are	many,	and	the	consequences	can	be	devastating	for	a	patient.	Several	toxins	have	been	reported	to	cause	clinical	demyelination	in	humans,	including	sodium	cyanate	and	the	antiseptic	hexachlorophene	[1].	However,	these	cases	are	rare	when	compared	to	the	autoimmune	diseases	multiple	sclerosis	and	neuromyelitis	optica,	or	even	genetic	mutations	as	occur	in	Pelizaeus-Merzbacher	disease	or	adrenoleukodystrophy.	Toxin-based	models	do	not	attempt	to	replicate	the	complex	pathogenesis	of	these	diseases,	but	rather	provide	a	reductionist	setting	to	study	certain	aspects,	where	kinetics	are	predictable	and	confounding	variables	minimised.	This	approach	has	yielded	substantial	insight	into	the	biology	of	demyelination	and	remyelination,	with	much	relevance	to	human	disease.	
1.1 Types of toxin-based model Due	to	the	diversity	in	the	range	of	toxins	used	to	cause	demyelination	and	their	modes	of	delivery,	this	chapter	will	focus	on	three	of	the	most	common	models.	Focal	injection	of	two	substances	(lysolecithin	and	ethidium	bromide)	will	be	discussed,	as	will	administration	of	cuprizone	in	the	diet.	Other	toxins	reported	to	cause	primary	demyelination	in	animal	models	include	6-aminonicotinamide	[2],	antibodies	to	myelin	proteins	(e.g.	[3])	and	bacterial	endotoxin	[4],	and	these	are	briefly	summarised	in	Table	1.		
Table	1:	Overview	of	toxin-based	models	for	demyelination/remyelination.	
Toxin Focal / Systemic Mechanism Principal uses 
Lysolecithin Focal	 • Detergent	effect	on	oligodendrocytes	
• Activates	immune	cells	 • Most	commonly	used	focal	model,	with	very	well-defined	kinetics	
• Electrophysiological	recordings	in	a	specific	location		
Ethidium Bromide Focal	 • Intercalates	in	DNA	
• Affects	all	nuclei	in	lesion,	sparing	axons	 • Remyelination	in	the	relative	absence	of	astrocytes	• Lesions	in	CCP	can	be	combined	with	an	in-dwelling	catheter	for	infusion	
Cuprizone Systemic	 • Disturbs	copper	homeostasis,	causing	metabolic	stress	
• Oligodendrocytes	are	especially	vulnerable	and	undergo	apoptosis	
• No	surgical	procedures	required	
• Remyelination	with	intact	blood-brain	barrier	[5]	
• Similarities	with	pattern	III	lesions	in	multiple	sclerosis	[6]	
6-aminonicotinamide Focal,	with	systemic	effects	on	grey	matter	 • Likely	to	involve	vitamin	B3	(nicotinic	acid)	antagonism	causing	gliotoxicity	[7]	
• Remyelination	in	the	relative	absence	of	astrocytes	
(Largely	superseded	by	other	
models)	
Anti-galactocerebroside 
+ complement 
Focal	 • Antibody	against	a	major	constituent	of	myelin	causes	selective	fixation	of	complement	
• Highly	axon-sparing	lesion	
Bacterial endotoxin 
(lipopolysaccharide) 
Focal	 • Direct	Toll-Like	Receptor	signalling	to	oligodendrocytes	and	astrocytes	[8]	
• Activates	immune	cells	
• Focal	model	of	immune-mediated	demyelination	
• Similarities	with	pattern	III	lesions	in	multiple	sclerosis	[4]		
1.1.1 Lysolecithin Lysolecithins	(lysophosphatidylcholines,	LPCs)	are	hydrolysis	products	of	phospholipids,	which	are	found	naturally	in	cell	membranes	and	have	physiological	roles	in	mediating	the	phagocytosis	of	apoptotic	cells	[9].	The	demyelination	literature	typically	refers	to	the	singular	lysolecithin	
(lysophosphatidylcholine),	which	is	in	fact	a	mixture	of	lysolecithins	with	different	fatty	acid	tails,	prepared	by	the	enzymatic	action	of	phospholipase	A2	on	a	natural	substrate	rich	in	phospholipids	such	as	egg	yolk	(for	example:	Sigma	L4129).	Focal	injection	of	lysolecithin	was	first	shown	to	cause	CNS	demyelination	in	the	mouse	spinal	cord	in	the	1970s	[10]	and	subsequent	studies	have	shown	similar	lesions	in	other	species	including	rat	[11]	and	rabbit	[12],	and	other	white	matter	tracts	such	as	the	corpus	callosum	[13]	and	caudal	cerebellar	peduncle	(CCP)[14].		Lysolecithin	selectively	destroys	myelin,	and	kills	the	majority	of	oligodendrocytes	[15]	in	an	ellipsoid	region	spanning	several	millimetres.	Following	injection,	there	is	marked	inflammation	in	the	core	of	the	lesion	with	astrogliosis	at	the	border	[16].	Axonal	injury	can	be	more	pronounced	than	in	other	toxin-based	models.	Remyelination	occurs	extensively	and	rapidly	in	
young	animals	(within	one	month	in	the	young	adult	mouse	[16])	and	is	mainly	carried	out	by	new	oligodendrocytes,	generated	from	oligodendrocyte	progenitor	cells	(OPCs)[17].	Remyelination	by	Schwann	cells	can	also	occur	in	the	centre	of	a	lesion,	particularly	if	it	is	large	or	there	is	excessive	astrocyte	loss.	In	older	animals	the	regeneration	of	myelin	sheaths	occurs	more	slowly	[18].		The	demyelinating	action	of	lysolecithin	is	likely	a	combination	of	two	effects	(Fig	1a).	Firstly,	being	made	up	of	amphipathic	molecules,	concentrated	lysolecithin	can	act	as	a	detergent,	compromising	the	integrity	of	cell	membranes	[19].	Oligodendrocytes	are	particularly	vulnerable	to	this	effect,	which	may	be	in	part	because	other	cell	types	are	able	to	metabolise	lysolecithin,	limiting	its	concentration	in	their	membranes	[20].	Secondly,	lysolecithin	can	signal	directly	to	immune	cells,	being	a	chemoattractant	signal	for	monocytes	and	lymphocytes	[21,	22]	and	direct	activator	of	monocytes,	macrophages,	microglia	and	lymphocytes	[23–25].	Thus	the	toxin	may	directly	activate	immune	cells	to	strip	axons	of	their	myelin,	which	is	already	compromised	by	the	detergent	action.	Evidence	for	an	immune-mediated	component	is	that	lysolecithin-induced	demyelination	is	reduced	when	immune	signalling	molecules	are	neutralised	[26],	or	in	mice	devoid	of	T	cells	[27].	Despite	these	roles	in	the	pathology,	macrophages,	microglia	and	T	cells	are	also	necessary	for	efficient	remyelination	[28–30].	Demyelination	does	not	depend	on	CXCR2+	neutrophils,	which	are	essential	in	the	cuprizone	model	[31].		By	virtue	of	its	relatively	high	selectivity	to	oligodendrocytes,	lysolecithin	can	also	been	used	to	study	demyelination	and	remyelination	in	organotypic	slice	culture.	Slices	of	cerebellum	several	hundred	micrometres	thick	are	most	commonly	used,	as	their	largely	self-contained	neural	networks	allows	good	survival	of	myelinated	Purkinje	cells	ex	vivo	[32].	This	model	has	been	successful	in	both	rat	[32]	and	mouse	tissue	[33]	and	has	proved	useful	for	screening	compounds	suspected	to	influence	remyelination	in	a	shorter	timescale	than	for	live	animals	[33–35].		
1.1.2 Ethidium bromide Ethidium	bromide	(EB)	is	a	planar	molecule	that	can	intercalate	between	base	pairs	in	double-stranded	DNA	[36]	to	inhibit	transcription	and	replication.	This	property	has	made	it	useful	as	a	veterinary	cytotoxic	drug	to	treat	trypanosomiasis	[37],	as	well	as	for	visualisation	of	nucleic	acids	for	research	purposes.	Focal	demyelination	by	EB	injection	into	a	white	matter	tract	was	first	demonstrated	in	the	spinal	cords	of	cats	in	the	1980s	[38]	and	has	since	become	well	established	in	mice	and	rats,	with	other	locations	including	the	CCP	white	matter	tract	[14]	and	the	grey	matter	of	the	hippocampus	[39].		Injected	EB	is	cytotoxic	to	any	cell	with	a	cell	body	in	the	lesion	area	(Fig	1b).	This	will	include	oligodendrocytes	and	astrocytes	[38]	as	well	as	OPCs	[40],	but	axons	projecting	from	distant	nuclei	are	spared,	providing	especially	high	doses	are	not	used.	This	means	that	EB	and	lysolecithin	lesions	differ	in	some	crucial	respects.	EB	lesions	tend	to	be	larger	and	remyelination	occurs	more	slowly,	likely	due	to	the	death	of	progenitor	cells	and	astrocytes/microglia,	which	must	
be	recruited	from	surrounding	intact	tissue	[14].	The	death	of	astrocytes	also	results	in	an	increased	contribution	of	Schwann	cells	to	remyelination,	as	astrocytes	inhibit	OPCs	from	adopting	a	Schwann	cell	fate	[41,	42].	Clearance	of	myelin	debris	is	frequently	delayed	in	EB	lesions,	contributing	to	a	slower	rate	of	remyelination	[43,	44],	a	probable	consequence	of	microglial	death	and	an	impaired	inflammatory	response.	Thus	comparisons	between	EB	and	lysolecithin	lesions	have	helped	to	disentangle	some	of	the	important	roles	that	astrocytes	and	microglia	play	in	remyelination.		
1.1.3 Cuprizone In	contrast	to	the	focal	injection	of	lysolecithin	or	ethidium	bromide,	the	copper	chelator	cuprizone	(biscyclohexanone	oxalyldihyrazone)	is	administered	to	animals	in	their	diet.	This	abrogates	the	need	for	surgical	equipment	and	expertise,	making	it	the	toxin-based	model	of	choice	for	many	groups	studying	remyelination.	Since	the	1960s,	cuprizone	has	been	known	to	cause	demyelination	in	mice	[45]	though	subsequent	studies	using	a	range	of	species,	strains,	ages	and	doses	showed	much	variability	in	the	degree	of	demyelination.	To	achieve	consistency	and	reproducibility,	most	experimenters	feed	a	0.2%	cuprizone	diet	to	young	adult	male	C57BL/6	mice	for	a	period	of	4-6	weeks,	which	has	been	shown	to	give	a	predictable	pattern	of	demyelination	with	the	scope	for	transgenic	studies	[46].		Demyelination	occurs	most	notably	in	the	corpus	callosum,	but	also	at	other	sites	including	the	hippocampus,	external	capsule,	cerebellar	peduncles	and	cerebral	cortex	[47].	Callosal	demyelination	becomes	gradually	apparent	from	3	weeks	of	treatment,	and	is	accompanied	by	extensive	inflammation	and	astrogliosis	[46].	The	corpus	callosum	is	most	affected	towards	its	caudal	end	(Fig	2),	thus	it	is	important	that	equivalent	locations	are	selected	for	meaningful	comparison	[47].	Remyelination	overlaps	with	continued	demyelination:	at	3	weeks	OPCs	begin	to	accumulate	[48]	and	mRNA	for	myelin	proteins	is	detected	from	week	5	[49].	Often	the	mice	are	returned	to	their	regular	diet	for	1-2	weeks	to	allow	a	period	of	remyelination	in	the	absence	of	active	demyelination.	Remyelination	is	substantial	after	a	3	weeks	recovery,	with	restoration	of	the	perinodal	architecture	[50],	although	this	may	not	entail	complete	functional	regeneration	as	axonal	degeneration	and	locomotor	impairment	can	reappear	several	months	later	[51].		Cuprizone	has	a	high	affinity	for	copper,	an	important	cofactor	for	metabolic	reactions	including	oxidative	phosphorylation	in	mitochondria.	However,	the	exact	mechanism	by	which	it	causes	demyelination	remains	a	matter	of	controversy	[52].	One	hypothesis	suggests	that	the	toxin	itself	remains	in	the	gut,	where	it	chelates	copper	and	brings	about	a	systemic	deficiency	and	failure	of	copper-dependent	processes	[53,	54].	An	alternative	theory	proposes	that	cuprizone	can	distribute	into	the	plasma	and	CNS,	where	it	locally	disrupts	the	homeostasis	of	copper	and	other	metals	[55,	56].	In	any	case,	dietary	cuprizone	treatment	leads	to	disturbances	in	cellular	metabolism	and	selective	apoptosis	of	oligodendrocytes,	which	are	particularly	vulnerable	due	to	their	high	metabolic	rate	and	low	levels	of	antioxidants	(Fig	1c)[56,	57].	OPCs	and	astrocytes	are	
largely	spared,	the	latter	of	which	are	also	thought	to	protect	neurons	through	metabolic	coupling	[52].	However,	it	is	important	to	note	that	cuprizone	is	a	systemic	toxin	and	will	likely	have	off-target	effects	in	the	CNS	as	well	as	other	tissues	-	notably	the	liver	[58].		An	initial	phase	of	early	oligodendrocyte	death	[59]	is	exacerbated	by	a	second	hit	from	the	immune	system.	Full	demyelination	depends	on	the	actions	of	neutrophils	[31]	and	microglia	[60]	but	not	lymphocytes	[61].	However,	as	with	lysolecithin	and	EB	lesions,	the	innate	immune	system	also	plays	a	vital	role	in	remyelination,	by	clearing	debris	and	secreting	growth	factors	[30,	62,	63].		Aspects	of	the	cuprizone	paradigm	can	be	modified	to	suit	the	specific	needs	of	an	experiment.	A	common	version	is	the	“chronic”	cuprizone	model,	whereby	mice	receive	a	12-week	course	of	cuprizone	and	show	impaired	remyelination	with	more	axonal	damage	[64,	65].	In	another	variation,	mice	receive	the	mTOR	inhibitor	rapamycin,	which	blocks	OPC	differentiation	and	delays	remyelination	until	the	end	of	cuprizone	treatment	[66].	This	allows	separation	of	the	demyelination	and	remyelination	phases,	as	seen	in	lysolecithin	or	EB	lesions,	though	the	effect	of	rapamycin	on	the	microglial	and	astrocyte	responses	remains	to	be	fully	characterised.		
1.2 Why use toxin-based models to study demyelination and remyelination? Toxin-based	models	are	just	one	strategy	to	model	myelin	diseases	in	vivo,	and	should	therefore	be	considered	alongside	other	approaches.	Alternatives	include	autoimmune	models	such	as	Experimental	Autoimmune	Encephalomyelitis	(EAE)	[67,	68],	and	infectious	models	such	as	Theiler’s	Murine	Encephalomyelitis	(TMEV)[69,	70],	which	are	generally	better	representations	of	the	effector	aspects	of	multiple	sclerosis.	Genetic	models	have	also	furthered	our	understanding,	for	example	the	effects	of	mutations	that	cause	myelin	disease	can	be	modelled	in	transgenic	mice	[71].		A	key	strength	of	toxin-based	models	is	their	predictability,	both	in	their	temporal	and	spatial	patterns.	Lysolecithin	and	EB	lesions	demonstrate	a	consistent	sequence	of	events	with	daily	resolution,	giving	a	clear	background	on	which	to	study	factors	that	may	influence	the	rate	of	demyelination	or	remyelination.	Cuprizone	also	has	a	predictable	course,	albeit	over	a	longer	timescale.	This	is	in	contrast	to	EAE,	where	the	sites	of	demyelination	will	vary	between	animals,	and	lesions	of	different	ages	will	occur	in	the	same	animal,	complicating	interpretation.	Focal	lesions	of	specific	white	matter	tracts	can	also	be	favourable	for	animal	welfare,	with	phenotypes	generally	less	severe	than	in	EAE	[72].		A	separation	between	the	demyelination	and	remyelination	phases	is	another	feature	of	the	lysolecithin	and	EB	models.	Whilst	this	does	not	recapitulate	the	natural	history	of	diseases	such	as	multiple	sclerosis,	it	has	allowed	pathways	involved	in	pathology	and	regeneration	to	be	disentangled.	A	notable	example	was	identifying	the	positive	contribution	of	the	innate	immune	system	to	
remyelination	[28],	which	is	obscured	in	other	models	by	its	roles	in	myelin	damage.		Toxin-based	models	have	generally	been	viewed	as	reductionist	tools,	whilst	EAE	and	viral	models	are	used	as	our	best	approximations	to	human	disease.	However,	there	is	much	heterogeneity	between	lesions	in	multiple	sclerosis	and	some	may	in	fact	be	better	modelled	using	toxin-based	approaches.	For	example	cuprizone	is	thought	to	be	one	of	the	best	experimental	models	for	pattern	III	clinical	demyelination	[6].	It	is	clear	that	a	continued	synthesis	of	results	from	different	approaches	is	necessary	to	advance	the	field	of	myelin	research.	Toxin-based	models	can	be	a	valuable	resource,	so	long	as	the	strengths	and	limitations	are	considered	and	the	choice	of	model	is	well	suited	to	answer	the	question	at	hand.	 	
2. Materials Protocols	for	a	typical	paradigm	using	each	of	our	three	toxins	will	be	described:	
• lysolecithin	-	focal	injection	into	mouse	ventral	spinal	cord	
• ethidium	bromide	-	focal	injection	into	rat	caudal	cerebellar	peduncle	
• cuprizone	-	dietary	administration	
2.1 Focal injection models Lysolecithin	and	ethidium	bromide	are	both	focally	injected	under	anaesthesia	and	much	of	the	equipment	required	is	common	to	both.		
Materials	required	for	lysolecithin	spinal	cord	lesions:	 	
• 1%	lysolecithin	(see	below)	-	at	least	1	μl	per	lesion	
• Sterile	gown	and	gloves	
• Anaesthetic	machine	(isoflurane	in	oxygen)	
o An	injectable	anaesthetic	may	be	used	if	an	inhalation	set-up	is	not	available.	
• Operating	table	with	a	stage	for	mouse	and	two	surgical	stands	
• 3-way	manipulator	for	Hamilton	syringe	
• Operating	microscope	
• Heat	pad	and	rectal	probe	to	monitor	temperature	
• Clippers	
• Disposable	drapes	
• Gauze	swabs	
• Viscotears	(Alcon)	
• Antiseptic	solution	e.g.	Betadine®	
• Sterile	saline		
• Analgaesic	e.g.	buprenorphine,	0.05	mg/kg	(Vetergesic	(Champion	Alstoe)	contains	0.3	mg/ml	buprenorphine,	so	can	be	diluted	1	in	6	in	saline	and	used	100	μl/100	g)	
• Cotton	wool	or	similar	(for	bleeding)	
• Instruments:	
o Hamilton	syringe	with	glass	tip	for	injecting	lysolecithin	
o 30G	dental	needle	to	cut	dura	
o 5	ml	syringe	and	needle	to	administer	saline	
o 1	ml	syringe	and	needle	to	administer	analgaesic	
o Scalpel	with	small	blade	(e.g.	No.	15)	
o Fine-tipped	tweezers	(2	sets)	
o Mosquito	forceps	
o Needle	holder	
o Scissors	
• 6-0	sutures	
• Recovery	unit		Lysolecithin	should	be	prepared	in	advance.	Add	10	ml	sterile	saline	to	100	mg	lysolecithin	(Sigma	L4129),	dissolve,	then	make	aliquots	to	freeze	at	-20°C.	On	the	day	of	lesioning,	defrost	aliquot	and	sonicate	in	a	sonicating	water	bath	for	20-30	minutes	until	clear.		
Materials	required	for	ethidium	bromide	CCP	lesions:	 	
• 0.01%	ethidium	bromide	(see	below)	-	at	least	4μl	per	lesion	
• Sterile	gown	and	gloves	
• Anaesthetic	machine	(isoflurane	in	oxygen)	
o An	injectable	anaesthetic	may	be	used	if	an	inhalation	set-up	is	not	available.	
• Operating	table	with	a	small	animal	stereotactic	frame	
• Operating	microscope	
• Heat	pad	and	rectal	probe	to	monitor	temperature	
• Clippers	
• Disposable	drapes	
• Gauze	swabs	
• Viscotears	(Alcon)	
• Antiseptic	solution	e.g.	Betadine®	
• Sterile	saline		
• Analgaesic	e.g.	buprenorphine,	0.05	mg/kg	(Vetergesic	(Champion	Alstoe)	contains	0.3	mg/ml	buprenorphine,	so	can	be	diluted	1	in	6	in	saline	and	used	100	μl/100	g)	
• Cotton	wool	or	similar	(for	bleeding)	
• Instruments:	
o 10ml	Hamilton	syringe	with	26G	cone	tip	needle	for	injecting	EB	
o 5ml	syringe	and	needle	to	administer	saline	
o 1ml	syringe	and	needle	to	administer	analgaesic	
o Scalpel	with	small	blade	(e.g.	No.	15)	
o Surgical	drill	
o Retractor	
o Needle	holder	
o Scissors	
• 5-0	sutures	
• Recovery	unit		Ethidium	bromide	can	be	purchased	as	a	liquid	and	diluted	in	PBS	to	0.01%.	
2.2 Dietary cuprizone model 
Materials	required	for	the	cuprizone	model:	
• cuprizone	diet	(see	below)	
• biological	safety	cabinet	to	open	cages	
• scales	for	weighing	mice		The	easiest	option	is	to	purchase	a	diet	with	cuprizone	incorporated	at	0.2%.	A	number	of	suppliers	are	able	to	provide	this,	including	Envigo	(TD.140804)	and	SDS	(as	a	“Custom	Made	Diet”).	A	common	alternative	is	to	buy	cuprizone	separately	and	mix	it	with	powdered	chow.	The	diet	should	not	be	autoclaved,	as	cuprizone	is	heat-sensitive,	and	it	should	be	stored	in	the	dark	and	refrigerated.	
  
3. Methods Surgical	procedures	should	be	carried	out	wearing	a	sterile	gown	and	gloves,	with	good	aseptic	technique.	
3.1 PROTOCOL: Lysolecithin lesion in mouse ventral spinal cord Spinal	cord	lesions	are	normally	carried	out	on	mice	aged	8	weeks	and	onwards.	The	procedure	should	take	less	than	30	minutes	and	sterile	saline	can	be	applied	periodically	to	prevent	the	wound	from	drying	out.		 1. Prepare	anaesthetic	machine,	operating	microscope,	operating	table	with	stage	suitable	for	mice,	and	sterile	surgical	instruments.			2. Prepare	the	following	syringes:	
• Glass-tipped	Hamilton	syringe	with	1%	lysolecithin	-	ensure	there	are	no	bubbles	and	attach	this	to	a	3-way	manipulator	fitted	to	a	stand	
• 1	ml	syringe	of	analgaesic	e.g.	buprenorphine,	0.05	mg/kg.		3. Weigh	mouse	and	transfer	to	anaesthetic	chamber	to	begin	induction	of	anaesthesia	with	isoflurane/oxygen.	When	effective,	transfer	mouse	to	operating	stage	equipped	with	mask	for	maintaining	anaesthesia	throughout	the	procedure.	Position	mouse	prone	with	head	away	from	operator.		4. Inject	analgaesic	subcutaneously.	Position	the	temperature	probe	and	apply	1	drop	of	Viscotears	liquid	gel	to	each	eye.		5. Prepare	skin	by	shaving	the	back	around	the	natural	“hump”	and	clean	the	shaved	area	with	antiseptic	solution.	Do	not	treat	excessively	to	prevent	heat	loss.	Cut	a	small	access	window	in	a	sterile	drape	and	lay	over	mouse.		6. Begin	operating	after	verifying	the	mouse	has	no	response	to	pain.	Start	with	a	0.5	cm	midline	incision	at	the	top	of	the	hump	on	the	back	(thoraco-lumbar	region).	Cut	away	the	subcutaneous	tissue	to	expose	the	muscles.	Use	a	small	scalpel	blade	to	gently	separate	the	muscles	on	both	sides.		7. Under	the	microscope,	find	the	space	between	two	vertebrae	using	two	pairs	of	fine-tipped	tweezers	and	remove	the	soft	tissues:	first	muscle	and	then	the	yellow	ligament	to	expose	the	surface	of	the	spinal	cord.	This	should	appear	pale	with	the	central	vein	visible	in	the	midline.	Care	must	be	taken	not	to	damage	the	spinal	cord	at	this	stage.		8. Use	a	pair	of	curved	mosquito	forceps	to	clamp	the	soft	tissue	above	the	exposed	intervertebral	space,	then	fix	to	a	stand	to	minimise	movement	of	the	injection	site	from	breathing.	Use	a	very	thin	bevelled	needle	(such	as	a	30G	dental	needle)	to	open	the	dura	just	to	the	right	of	the	central	vein	(Fig	3).		
9. Position	the	manipulator	with	the	Hamilton	syringe	at	a	70°	angle	relative	to	the	horizontal	plane.	Gentle	adjust	the	tip	of	the	syringe	to	touch	the	surface	of	the	cord	through	the	cut	dura.	Slowly	lower	the	needle	through	the	cord,	until	a	slight	deflection	indicates	contact	with	the	vertebral	bone	underneath.	Retract	the	needle	fractionally	so	the	deflected	tip	becomes	straight.		10. Inject	0.5	μl	of	toxin	in	about	20	seconds,	then	retract	the	needle	about	0.2-0.25	mm	and	inject	another	0.5	μl.	Keep	the	needle	in	place	for	1	minute.		11. Slowly	raise	the	needle	out	of	the	spinal	cord.	And	move	away	clamp	and	manipulator.	Using	a	6-0	suture,	make	one	stitch	to	close	the	muscular	layer,	then	2-3	stitches	for	the	skin.	Lidocaine	cream	can	be	applied	to	reduce	pain	at	the	wound	site.		12. Transfer	the	mouse	to	a	warm	chamber	for	recovery	before	returning	it	to	the	cage.			After	the	procedure,	there	should	be	no	signs	of	distress	or	clinical	abnormality.	No	special	care	is	required	and	individual	cages	are	not	necessary.	Occasionally	a	mouse	may	develop	a	unilateral	hind	leg	impairment,	which	should	recover	in	within	48	hours	and	will	not	prevent	animal	accessing	food	or	water.	External	sutures	are	often	removed	by	the	mouse,	and	may	need	to	be	replaced	if	this	occurs	before	wound	closure.		
3.2 PROTOCOL: Ethidium bromide lesion in rat caudal cerebellar peduncle Lesions	of	the	CCP	are	typically	carried	out	on	rats	aged	8	weeks	and	onwards.	The	procedure	is	more	complex	than	spinal	cord	lesions	due	to	the	need	to	drill	through	the	skull	and	use	precise	stereotactic	coordinates.	In	total,	it	should	take	around	45-60	minutes.		 1. Prepare	anaesthetic	machine,	operating	microscope,	operating	table	with	stereotactic	frame,	and	sterile	surgical	instruments.		2. Prepare	the	following	syringes:	
• Hamilton	syringe	(with	26G	needle)	with	0.01%	ethidium	bromide	-	ensure	there	are	no	bubbles	and	attach	this	to	stereotactic	frame	
• 5	ml	syringe	of	sterile	saline	-	place	in	recovery	unit	to	warm	
• 1	ml	syringe	of	analgaesic	e.g.	buprenorphine,	0.05	mg/kg.		3. Weigh	rat	and	transfer	to	anaesthetic	chamber	to	begin	induction	of	anaesthesia	with	isoflurane/oxygen.	When	effective,	inject	analgaesic	(subcutaneous)	and	2.5-3	ml	saline	(intraperitoneal).	Position	the	temperature	probe.		4. Shave	top	of	head	from	between	the	eyes	to	behind	the	ears.	Scrub	area	with	two	gauze	swabs	wetted	with	antiseptic	solution	and	apply	1	drop	of	
Viscotears	liquid	gel	to	each	eye.		5. Transfer	rat	to	stereotactic	frame	equipped	with	mask	for	maintaining	anaesthesia	throughout	the	procedure.	Open	the	mouth	and	pull	tongue	outside	if	possible.	Attach	the	ear	bars	carefully,	holding	the	animal.	Each	bar	should	be	in	the	same	position	and	an	eye-closing	reflex	can	be	seen	when	the	bar	is	correctly	located.	The	head	of	the	animal	should	be	positioned	flat,	which	can	be	verified	once	the	skull	is	exposed.		6. Apply	skin	prep	to	the	shaved	area	skin.	Cut	a	small	access	window	in	a	sterile	drape	and	lay	over	rat.		7. Using	a	scalpel,	make	a	1.5	cm	midline	incision	at	the	back	of	the	head.	Remove	the	connective	tissue	with	scissors	and	forceps.	Cotton	wool	can	be	used	to	stop	the	bleeding.	Scrape	away	tissue	overlying	the	bone	with	the	scalpel.		8. With	the	aid	of	the	microscope,	locate	the	bregma	and	note	its	coordinates,	β	(Fig	4).	Touching	the	bones	to	move	them	slightly	can	aid	with	this.		9. Locate	the	lambda,	which	is	defined	as	the	midpoint	of	the	curve	of	best	fit	along	the	lambda	suture	(Fig	4)	rather	than	the	intersection	of	the	lambdoid	and	sagittal	sutures	[73].	Note	its	coordinates,	λ.		10. Confirm	that	β	and	λ	lie	on	the	same	horizontal	plane,	and	adjust	the	position	of	the	rat	as	necessary.		11. Calculate	the	stereotactic	coordinates	for	the	CCP	using	Table	2.	These	will	depend	on	the	size	of	the	rat,	and	thus	the	β-λ	distance.	
	
Table	2:	Guide	for	calculating	the	coordinates	of	CCP	relative	to	lambda,	λ		
12. Apply	the	retractor.	Position	tip	of	drill	at	the	point	of	entry.		13. Drill	through	the	skull,	advancing	slowly.	The	syringe	can	be	used	periodically	to	confirm	the	hole	is	in	the	correct	location.		14. When	drilling	is	complete,	move	the	syringe	to	the	calculated	coordinates	for	the	CCP.	The	coordinates	can	be	adjusted	slightly	if	the	needle	catches	on	the	edge	of	the	burr	hole.	This	is	preferable	to	allowing	the	needle	to	deflect,	which	may	result	in	the	tip	being	several	millimetres	away	from	the	intended	site.		
 Β-λ (mm) <8.0 8.0 - 8.2 8.2 - 8.5 8.5 - 9.0 9.0 - 9.5 >9.5 
Distance to 
CCP (mm) 
Anterior 2.1	 2.2	 2.2	 2.2	 2.3	 2.4	
Ventral 7.1	-	7.2	 7.2	 7.2	 7.2	 7.3	 7.4	
Lateral 2.5	 2.5	 2.5	 2.5	 2.6	 2.65	
15. Inject	4	μl	in	4	minutes,	then	wait	another	4	minutes.	Remove	the	syringe	slowly,	and	stop	any	bleeding.		16. Remove	the	retractor	and	close	the	skin	with	5-0	suture.		17. Transfer	the	rat	to	a	warm	chamber	for	recovery	before	returning	it	to	the	cage.			The	surgery	for	CCP	lesions	involves	more	risk	than	for	spinal	cord	lesions	(e.g.	haemorrhage)	and	post-operative	complications	are	also	more	common.	For	the	first	24	hours	after	the	procedure,	the	rat	should	be	housed	individually	and	provided	with	a	liquid/gel	diet	ad	libitum	and	a	long	spout	water	bottle.	If	showing	signs	of	pain,	another	dose	of	analgaesic	can	be	administered	several	hours	after	surgery.	Rats	are	often	lethargic	following	the	surgery	but	should	regain	their	usual	level	of	activity	over	2-3	days.	If	a	mild	head	tilt	develops	post-operatively,	this	should	be	monitored,	with	special	feeding	arrangements	as	required,	and	will	usually	resolve.	In	occasional	cases,	a	rat	may	develop	spontaneous	rolling	and	will	need	to	be	culled.	
3.3 PROTOCOL: Dietary administration of cuprizone to mice The	effects	of	cuprizone	can	depend	on	the	species,	strain,	age	and	gender	of	the	animals	used.	The	literature	standard	is	to	use	8-week	old	male	C57BL/6	mice,	and	feed	a	diet	of	0.2%	cuprizone	for	4-6	weeks	[52].		 1. For	a	period	of	4-6	weeks,	substitute	the	regular	feed	with	a	0.2%	cuprizone	diet.	This	should	be	replaced	every	2-3	days,	due	to	degradation	of	the	toxin.	Food	intake	can	be	estimated	as	4-5g	per	mouse	per	day.		2. Cuprizone	poses	a	safety	risk	through	skin	contact	or	inhalation.	For	this	reason,	mice	should	be	housed	in	sealed	cages	and	diet/bedding	changes	carried	out	in	a	biological	safety	cabinet	with	appropriate	waste	disposal.		3. Mouse	weights	should	be	monitored	throughout	the	experiment.	Weight	loss	often	occurs	during	the	first	1-2	weeks	of	administration,	with	subsequent	weight	gain.		4. Mice	are	often	returned	to	their	regular	diet	for	1-2	weeks	for	a	period	of	remyelination	without	ongoing	demyelination.		Under	these	conditions,	substantial	demyelination	is	achieved	whilst	minimising	clinical	severity,	which	is	frequent	at	higher	doses	[46,	74].	However,	some	weight	loss	is	common	and	other	signs	have	been	reported	including	reduced	social	interaction	[75]	and	impaired	performance	on	a	balance-beam	task	[76].				 	
4. Notes 
4.1 Identifying Remyelination Several	methods	can	be	used	to	visualise	and	quantify	myelin,	including	immunohistochemistry	for	myelin	protein,	light	microscopy	dyes	including	luxol	fast	blue	or	lipophilic	fluorophores	such	as	FluroMyelin	(ThermoFisher).	Magnetic	resonance	imaging	(MRI)	can	also	be	useful	tool	to	map	myelin	across	the	entire	brain.	However,	these	techniques	are	unable	to	distinguish	between	the	myelin	produced	during	remyelination	and	that	originating	in	development.	Thus,	it	can	be	difficult	to	determine	whether	an	intervention	has	truly	enhanced	remyelination,	or	if	more	of	the	original	sheaths	have	survived.		At	a	higher	resolution	it	becomes	clear	that	the	dimensions	of	the	myelin	relative	to	its	axon	differs	between	myelination	and	remyelination.	During	development,	myelin	sheath	thickness	increases	with	larger	diameter	axons.	In	remyelination,	this	relationship	is	not	maintained	and	thus	a	given	diameter	axon	will	be	myelinated	by	a	sheath	which	appears	thinner	and	with	shorter	internodes	than	developmentally	generated	myelin	(Fig	5)	[77].	To	be	able	to	visualise	this,	the	ultrastructure	of	the	tissue	must	be	very	well	preserved,	and	this	is	best	done	by	perfusion-fixing	animals	in	gluteraldehyde	before	embedding	regions	of	interest	resin	[78].	Myelin	sheath	thickness	can	then	be	measured	using	1	μm	sections	stained	with	toluidine	blue	(with	practice),	or	using	electron	microscopy.	The	thinner	sheaths	are	less	clear	in	regions	of	the	CNS	with	smaller-diameter	axons	such	as	the	corpus	callosum,	which	can	be	problematic	for	interpreting	electron	microscopy	in	the	cuprizone	model	[74].	
4.2 Other outcome measures for toxin-based models Besides	imaging	myelin	sheaths	themselves	a	wide	variety	of	techniques	have	been	applied	to	toxin-induced	lesions	to	study	the	cells	and	molecular	cues	involved	in	demyelination	and	remyelination.	To	preserve	the	CNS	for	immunohistochemistry,	a	perfusion-fixation	method	using	4%	paraformaldehyde	in	PBS	is	recommended.	This	delivers	fixative	rapidly	and	uniformly	to	all	tissues,	and	is	thus	preferable	to	immersion-fixation	[79].	In	situ	hybridisation	is	a	useful	alternative	to	immunohistochemistry,	particularly	to	visualise	transcripts	encoding	secreted	factors	or	myelin	sheath	proteins,	which	would	be	difficult	to	relate	to	a	cell	body.		Flow	cytometry	has	been	applied	to	dissected	lesion	tissue	with	some	success	in	the	cuprizone	model,	although	as	the	effected	regions	are	relatively	small	this	requires	pooling	of	large	numbers	of	mice	[62].	In	the	lysolecithin	model,	inflammatory	cells	from	the	lesion	and	normal	tissue	have	proved	difficult	to	separate	by	flow	cytometry,	probably	due	to	the	small	volume	of	affected	tissue	[80]	relative	to	the	more	global	inflammation	which	makes	this	possible	in	EAE	[81].	In	contrast	to	live	cells,	RNA	and	protein	from	a	small	region	of	CNS	containing	a	lysolecithin	lesion	have	been	reliably	used	to	investigate	remyelination	[82,	83].	Total	RNA	has	been	successfully	extracted	from	EB	lesions	very	selectively	using	laser	capture	microdissection	of	frozen	sections	[35],	revealing	general	patterns	in	gene	expression	at	different	timepoints	during	
remyelination.		
4.3 Conclusions Toxin-based	models	can	offer	a	valuable	insight	into	the	mechanisms	of	myelin	diseases,	and	into	broader	aspects	of	regenerative	medicine	[84].	Predictable	kinetics	and	a	temporal	dissociation	between	demyelination	and	remyelination	are	advantages	of	these	paradigms	that	complement	the	findings	of	other	model	systems.		
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Figures 
Figure	1:	Schematic	overview	of	the	mechanisms	by	which	lysolecithin	(a),	ethidium	bromide	(b)	and	cuprizone	(c)	cause	demyelination.		
	
	 	
Figure	2:	T2*-weighted	gadolinium-enhanced	Magnetic	Resonance	Image	(MRI)	of	brain	hemispheres	from	a	mouse	fed	a	0.2%	cuprizone	diet	for	5	weeks	(right)	and	a	control	animal	(left).	Myelin	appears	dark.	The	cuprizone-treated	mouse	shows	marked	demyelination	in	the	corpus	callosum	(white	boxes),	seen	here	at	its	caudal	end.		
	
	
	
	
Figure	3:	Injection	of	lysolecithin	into	the	ventral	white	matter	of	the	spinal	cord.	
	
	 	
Figure	4:	The	dorsal	surface	of	the	rat	skull.	The	lamba,	λ,	is	defined	as	the	midpoint	of	the	curve	of	best	fit	along	the	lambdoid	suture,	rather	than	the	intersection	between	the	lambdoid	and	sagittal	sutures.	
	
	
	
Figure	5:	Electron	micrographs	of	unlesioned	white	matter,	demyelination	and	remyelination,	highlighting	the	thinner	appearance	of	the	remyelinated	sheaths
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